Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
SABCS 2018TNBC Study of Capecitabine Mostly Disappoints, With One ExceptionA study of adjuvant capecitabine in triple-negative breast cancer was largely negative, but disease-free and overall survival were improved in a subset of patients with the nonbasal-like phenotype.
Medscape Medical News, December 5, 2018
Meeting Highlights At A Glance
Top News From SABCS 2018: SlideshowThis year prominently featured major trials showing data in support of: a reduced dose and duration of tamoxifen for DCIS;
partial breast irradiation; and a new standard of care when early-stage HER2+ disease is not cleared.
Top News From SABCS 2017: SlideshowHot topics include new data on the optimum duration of adjuvant therapy, the efficacy of trastuzumab in HER2–negative tumors,
and the advantages of dose-dense chemotherapy.
'Intriguing': 9 Weeks of Trastuzumab for Breast CancerNine weeks of therapy fell short of being noninferior to 12 months for the primary outcome, but overall survival was comparable,
and the shorter course is less toxic and less expensive.
